306 related articles for article (PubMed ID: 36420256)
1. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.
Hartinger JM; Kratky V; Hruskova Z; Slanar O; Tesar V
Front Immunol; 2022; 13():1024068. PubMed ID: 36420256
[TBL] [Abstract][Full Text] [Related]
2. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H
Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170
[TBL] [Abstract][Full Text] [Related]
3. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
4. A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis.
Hartinger JM; Šíma M; Hrušková Z; Pilková A; Krátký V; Ryšavá R; Jančová E; Bobek D; Douša J; Francová I; Tesař V; Slanař O
Biomed Pharmacother; 2024 Jun; 175():116655. PubMed ID: 38678967
[TBL] [Abstract][Full Text] [Related]
5. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
Basu B; Angeletti A; Islam B; Ghiggeri GM
Front Immunol; 2022; 13():805697. PubMed ID: 35222385
[TBL] [Abstract][Full Text] [Related]
6. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
Front Immunol; 2020; 11():566732. PubMed ID: 33384685
[TBL] [Abstract][Full Text] [Related]
7. Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.
Deng L; Xu G
Drugs; 2023 Apr; 83(6):507-530. PubMed ID: 37017915
[TBL] [Abstract][Full Text] [Related]
8. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
9. Current perspective on rituximab in rheumatic diseases.
Schioppo T; Ingegnoli F
Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750
[TBL] [Abstract][Full Text] [Related]
10. Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.
Oomen I; Nassar-Sheikh Rashid A; Bouts AHM; Gouw SC; Kuijpers TW; Rispens T; de Vries A; Wolbink G; van den Berg JM; Schonenberg-Meinema D
Clin Exp Rheumatol; 2022 Jan; 40(1):183-190. PubMed ID: 34251329
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.
Braun-Moscovici Y; Butbul-Aviel Y; Guralnik L; Toledano K; Markovits D; Rozin A; Nahir MA; Balbir-Gurman A
Rheumatol Int; 2013 Jun; 33(6):1495-504. PubMed ID: 23239037
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C; Wuest B; Crowley C; Boyman O
Front Immunol; 2021; 12():788830. PubMed ID: 35185862
[TBL] [Abstract][Full Text] [Related]
13. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.
Conversano E; Debiec H; Colucci M; Emma F; Ronco P; Vivarelli M
Pediatr Nephrol; 2024 Jan; 39(1):305-308. PubMed ID: 37466865
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
Kattah AG; Fervenza FC; Roccatello D
Autoimmun Rev; 2013 Jun; 12(8):854-9. PubMed ID: 23000633
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
17. Rituximab use in adult glomerulopathies and its rationale.
Santos JE; Fiel D; Santos R; Vicente R; Aguiar R; Santos I; Amoedo M; Pires C
J Bras Nefrol; 2020 Mar; 42(1):77-93. PubMed ID: 31904761
[TBL] [Abstract][Full Text] [Related]
18. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
Cagnoli L;
G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
[TBL] [Abstract][Full Text] [Related]
19. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
20. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
